Retrieved on:
Wednesday, April 24, 2024
ROCKVILLE, Md., April 24, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 29, 2024.
Key Points:
- ROCKVILLE, Md., April 24, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 29, 2024.
- Panel: Gene Therapy: Positioning for CMC Success at Every Stage at 4:00 p.m. EDT
A live webcast of the panel can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com .
- An archived replay of the webcast will be available for approximately 30 days following the presentation.
Retrieved on:
Wednesday, March 27, 2024
ROCKVILLE, Md., March 27, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days on Wednesday, April 3, 2024.
Key Points:
- ROCKVILLE, Md., March 27, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days on Wednesday, April 3, 2024.
- A live webcast of the fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com .
- An archived replay of the webcast will be available for approximately 30 days following the presentation.
ROCKVILLE, Md., March 11, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate the following upcoming investor conferences:
Key Points:
- ROCKVILLE, Md., March 11, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate the following upcoming investor conferences:
Gene Therapy Regulatory Path in Rare Diseases Panel: Wednesday, March 13, 2024 at 4:35 p.m.
- ET
A live webcast of the fireside chat at the Barclays conference can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com .
- An archived replay of the webcast will be available for approximately 30 days following the presentation.
Jess,
CK,
Hospital,
Duchenne muscular dystrophy,
Arkansas Children's Hospital,
Safety,
Human,
Immunosuppression,
Patient,
Phase,
Ageing,
Serum,
Pharmaceutical industry ROCKVILLE, Md., March 5, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today reported additional interim safety and efficacy data in the Phase I/II AFFINITY DUCHENNE® trial of RGX-202 in patients with Duchenne muscular dystrophy (Duchenne) ages 4 to11 years old, including RGX-202 microdystrophin expression from dose level 2 and video of trial clinic assessments demonstrating initial evidence of strength and functional improvement.
Key Points:
- ROCKVILLE, Md., March 5, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today reported additional interim safety and efficacy data in the Phase I/II AFFINITY DUCHENNE® trial of RGX-202 in patients with Duchenne muscular dystrophy (Duchenne) ages 4 to11 years old, including RGX-202 microdystrophin expression from dose level 2 and video of trial clinic assessments demonstrating initial evidence of strength and functional improvement.
- "RGX-202 at dose level 2 is demonstrating significantly increased microdystrophin expression in a 12-year-old patient," said Kenneth T. Mills, President and CEO, REGENXBIO.
- In addition, we are encouraged by the safety data at both dose levels and initial caregiver observations of strength and motor function improvement in boys treated with RGX-202.
- "I am very pleased with the new microdystrophin expression data from RGX-202 dose level 2.
Retrieved on:
Thursday, February 29, 2024
EST,
Duchenne muscular dystrophy,
Arkansas Children's Hospital,
Conference,
Interim,
Webcast,
Publication,
Phase,
PPMD,
Episcopal conference,
Pharmaceutical industry Company to host webcast on Tuesday, March 5, 2024 at 8:30 a.m. EST
Key Points:
- Company to host webcast on Tuesday, March 5, 2024 at 8:30 a.m. EST
Interim clinical data will be presented by Aravindhan Veerapandiyan, M.D., primary investigator of the AFFINITY DUCHENNE trial, at the MDA Clinical & Scientific Conference on Wednesday, March 6, 2024 at 12:00 p.m. EST
ROCKVILLE, Md., Feb. 29, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a live webcast to discuss new interim clinical data from the Phase I/II AFFINITY DUCHENNE® trial of RGX-202 for the treatment of Duchenne muscular dystrophy.
- Primary investigator Aravindhan Veerapandiyan, M.D.
- Access: The live webcast can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com .
- An archived replay of the webcast will be available for approximately 30 days following the presentation.
Retrieved on:
Wednesday, February 21, 2024
ROCKVILLE, Md., Feb. 21, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Tuesday, February 27, 2024, at 4:30 p.m.
Key Points:
- ROCKVILLE, Md., Feb. 21, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Tuesday, February 27, 2024, at 4:30 p.m.
- ET to discuss its financial results for the fourth quarter and full year ended December 31, 2023, and recent operational highlights.
- A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion.
- Those who plan on participating are advised to join 15 minutes prior to the start time.
Retrieved on:
Wednesday, January 31, 2024
Hospital,
Trial of the century,
Syndrome,
Central nervous system,
Hunter syndrome,
MPS II,
MPS,
Phase,
Glycogen storage disease,
Webcast,
Medical device ROCKVILLE, Md., Jan. 31, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations on its program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, will be shared at the 20th Annual WORLDSymposium™ 2024, taking place in San Diego, CA February 3-9, 2024.
Key Points:
- ROCKVILLE, Md., Jan. 31, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations on its program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, will be shared at the 20th Annual WORLDSymposium™ 2024, taking place in San Diego, CA February 3-9, 2024.
- The presentations include the topline results from the pivotal phase of the Phase I/II/III CAMPSIITE® trial of RGX-121 for the treatment of MPS II.
- The poster presentations will be presented as follows:
REGENXBIO will host a conference call Wednesday, February 7 at 4:30 p.m.
- A replay of the webcast will also be available via the Company's investor website approximately two hours after the call's conclusion.
Retrieved on:
Wednesday, January 10, 2024
Suprachoroidal drug delivery,
ABBV,
AAV,
Hawaiian Eye,
FACS,
Diabetic retinopathy,
AMD,
Webcast,
AbbVie,
Phase,
EST ROCKVILLE, Md., Jan. 10, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present data from the Phase II AAVIATE® trial of suprachoroidal ABBV-RGX-314 for the treatment of wet age-related macular degeneration (AMD) at Hawaiian Eye and Retina 2024 Meeting being held January 13-19, 2024 in Maui, HI.
Key Points:
- ROCKVILLE, Md., Jan. 10, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present data from the Phase II AAVIATE® trial of suprachoroidal ABBV-RGX-314 for the treatment of wet age-related macular degeneration (AMD) at Hawaiian Eye and Retina 2024 Meeting being held January 13-19, 2024 in Maui, HI.
- ABBV-RGX-314 is an investigational one-time AAV Therapeutic being developed in collaboration with AbbVie for the treatment of wet AMD, diabetic retinopathy and other additional chronic retinal conditions.
- Those who plan on participating are advised to join 15 minutes prior to the start time.
- A replay of the webcast will also be available via the Company's investor website approximately two hours after the call's conclusion.
10,526,617 ('617), from Penn, which is a joint plaintiff in the lawsuit.
Key Points:
- 10,526,617 ('617), from Penn, which is a joint plaintiff in the lawsuit.
- The lawsuit was filed September 30, 2020, and a trial was scheduled for the end of January 2024.
- A separate patent infringement action on a different Penn patent brought by REGENXBIO and Penn against Sarepta in June 2023 is also pending.
- The term of the '274 patent extends to October 2027 and damages are being sought to compensate REGENXBIO and its licensor, Penn.
Retrieved on:
Tuesday, November 7, 2023
ROCKVILLE, Md., Nov. 7, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate the following upcoming investor conferences:
Key Points:
- ROCKVILLE, Md., Nov. 7, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate the following upcoming investor conferences:
A live webcast of the fireside chats can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com .
- An archived replay of the webcast will be available for approximately 30 days following the presentation.
